Is elevated ferritin in MASLD and metabolic syndrome driven by inflammation and oxidative stress rather than true iron overload?

Clinical and mechanistic evidence

• Inflammatory activation: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic syndrome (MetS) represent chronic, low-grade systemic inflammatory states. Visceral adiposity and lipid accumulation in the liver trigger the release of pro-inflammatory cytokines, specifically interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α).
• Acute-phase response: Serum ferritin acts as an acute-phase reactant. IL-6 directly stimulates the transcription of ferritin genes in the liver. This means serum ferritin levels frequently rise in response to systemic inflammation and oxidative stress, independent of total body iron stores.
• Dysmetabolic hyperferritinemia: This phenomenon—often termed dysmetabolic iron overload syndrome (DIOS) or dysmetabolic hyperferritinemia—occurs in approximately 20–30% of patients with MASLD. It is characterized by elevated serum ferritin (often ranging from 300 to over 1000 ng/mL) alongside normal or only slightly elevated transferrin saturation (typically <45%).
• Absence of true overload: Quantitative hepatic MRI and liver biopsies demonstrate that while mild hepatic iron accumulation can occur in a subset of these patients (DIOS), they do not exhibit the severe, parenchymal iron overload characteristic of hereditary hemochromatosis.

Mechanistic explanations

• Hepcidin dysregulation: The chronic inflammatory state in MASLD stimulates the overexpression of hepcidin (via the IL-6/STAT3 pathway). Elevated hepcidin levels degrade the iron exporter ferroportin, leading to intracellular iron trapping within macrophages and hepatocytes, which further increases ferritin synthesis without a corresponding increase in systemic iron absorption.
• Oxidative stress: Intracellular lipid accumulation (lipotoxicity) damages mitochondria and increases the production of reactive oxygen species (ROS). This oxidative stress independently upregulates ferritin translation via the iron regulatory protein (IRP)/iron responsive element (IRE) pathway to help sequester free intracellular iron and limit oxidative damage.

Bottom line

In patients with MASLD and metabolic syndrome, elevated serum ferritin is primarily a biomarker of chronic, low-grade metabolic inflammation and oxidative stress (acting as an acute-phase reactant) rather than an indicator of true systemic iron overload. Clinicians should evaluate transferrin saturation to differentiate this dysmetabolic hyperferritinemia from genetic hemochromatosis before initiating iron depletion therapies.